Why do companies want to remove RBV from the cocktail but keep IFN?
The point is not that VRTX and other companies want to keep ifn in the cocktail, but rather that it may be harder to get rid of ifn than to get rid of ribavirin. In any case, I would not attach much significance to the graphic in slide #7.
Market Data 
Markets 
AI
